A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

NCT ID: NCT00102206

Last Updated: 2021-11-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2007-05-31

Brief Summary

HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.

Detailed Description

HIV infected children and adolescents on anti-HIV treatment regimens have traditionally had more difficulty with non-adherence and drug resistance than adults, often resulting in virologic failure. Additionally, HIV infected children with extensive exposure to antiretrovirals (ARVs) are likely to have fewer therapeutic options for salvage therapy, and their physicians find it difficult to choose regimens that will keep the HIV infection under control. This study will compare the efficacy of three 4-drug ARV salvage regimens in treatment-experienced, HIV infected children and adolescents who have experienced virologic failure.

This study will last at least 96 weeks. Participants will be randomly assigned to one of three groups. Group 1A will receive a dual-PI based regimen of lopinavir/ritonavir (LPV/r), saquinavir (SQV), and the NRTIs emtricitabine (FTC) and abacavir sulfate (ABC). Group 1B will receive a dual-PI based regimen of LPV/r, SQV, FTC, and tenofovir disoproxil fumarate (TDF). Group 2 will receive an NRTI-only regimen of ABC, lamivudine, zidovudine, and TDF.

There will be 11 study visits during Step I of this study. Medical history, a physical exam, and blood collection will occur at all visits. Dual-energy x-ray absorptiometry (DEXA) scans will occur at study entry and at Weeks 24, 48, 72, and 96. Urine collection will occur at most visits; participants will also take part in adherence modules at most visits. Participants will be asked to complete a pill count form at Weeks 4 and 24. Additionally, some study participants will be asked to participate in an intensive pharmacokinetics study at Week 4.

Conditions

HIV Infections

Keywords

Treatment Experienced; Child

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Abacavir sulfate

Intervention Type: DRUG

Emtricitabine

Intervention Type: DRUG

Lamivudine

Intervention Type: DRUG

Lopinavir/ritonavir

Intervention Type: DRUG

Saquinavir

Intervention Type: DRUG

Tenofovir disoproxil fumarate

Intervention Type: DRUG

Zidovudine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• HIV infected
• No currently available therapeutic options that would likely result in long-term suppression of virus to less than 400 copies/ml
• Two measurements within 4 months prior to screening and at screening of either CD4% of less than 15% and HIV viral load of greater than 10,000 copies/ml OR HIV viral load greater than 30,000 copies/ml
• Previous exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs), NRTIs, and PIs AND have experienced virologic failure. More information on previous treatment regimen requirements is available in the protocol.
• Prior or current virologic failure with genotypic or phenotypic resistance OR historical virologic failure with a PI- or NNRTI-containing regimen
• Resistance to 2 or more drugs in most recent treatment regimen within 26 weeks prior to study screening
• Able and willing to swallow study medications
• Parent or guardian willing to provide informed consent, if applicable
• Willing to use acceptable methods of contraception

Exclusion Criteria

• Previous cumulative exposure to TDF for more than 24 weeks OR more than 14 days of TDF exposure during the 24 weeks prior to study entry
• Grade 1 lipase or higher within 28 days prior to study entry
• Grade 3 or higher laboratory abnormality (except for lipase) within 28 days prior to study entry
• History of allergy or hypersensitivity to any of the study drugs
• Active CDC Stage C opportunistic infection or serious bacterial infection requiring therapy at the time of screening
• Chemotherapy for active cancer
• Require certain medications
• Abnormal kidney function
• Any clinically significant diseases other than HIV infection or findings during medical history screening that, in the opinion of the investigator, may interfere with the study
• Pregnancy or breastfeeding

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role: collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew Wiznia, MD

Role: STUDY_CHAIR

Jacobi Medical Center

Ann J. Melvin, MD, MPH

Role: STUDY_CHAIR

Seattle Children's Hospital and Regional Medical Center

Locations

Chicago Children's CRS

Chicago, Illinois, United States

Columbia IMPAACT CRS

New York, New York, United States

SUNY Stony Brook NICHD CRS

Stony Brook, New York, United States

DUMC Ped. CRS

Durham, North Carolina, United States

Countries

Puerto Rico; United States

References

Brogly S, Williams P, Seage GR 3rd, Oleske JM, Van Dyke R, McIntosh K; PACTG 219C Team. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005 May 11;293(18):2213-20. doi: 10.1001/jama.293.18.2213.

Reference Type: BACKGROUND

PMID: 15886376 (View on PubMed)

Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs. 2002;4(9):581-607. doi: 10.2165/00128072-200204090-00004.

Reference Type: BACKGROUND

PMID: 12175273 (View on PubMed)

Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs. 2004;6(3):147-59. doi: 10.2165/00148581-200406030-00002.

Reference Type: BACKGROUND

PMID: 15170362 (View on PubMed)

Neely M, Kovacs A. Management of Antiretroviral Therapy in Neonates, Children, and Adolescents. Curr Infect Dis Rep. 2003 Dec;5(6):521-530. doi: 10.1007/s11908-003-0097-4.

Reference Type: BACKGROUND

PMID: 14642195 (View on PubMed)

Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. 1999 Jul 30;13(11):F71-7. doi: 10.1097/00002030-199907300-00001.

Reference Type: BACKGROUND

PMID: 10449277 (View on PubMed)

Other Identifiers

10131

Identifier Type: REGISTRY

Identifier Source: secondary_id

PACTG P1053

Identifier Type: -

Identifier Source: secondary_id

P1053

Identifier Type: -

Identifier Source: org_study_id